Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Apr;40(4):309-13.
doi: 10.1097/RLU.0000000000000670.

Initial experience using 99mTc-MIBI SPECT/CT for the differentiation of oncocytoma from renal cell carcinoma

Affiliations

Initial experience using 99mTc-MIBI SPECT/CT for the differentiation of oncocytoma from renal cell carcinoma

Steven P Rowe et al. Clin Nucl Med. 2015 Apr.

Abstract

Purpose: The differentiation of oncocytoma from renal cell carcinoma (RCC) remains a challenge with currently available cross-sectional imaging techniques. As a result, a large number of patients harboring a benign oncocytoma undergo unnecessary surgical resection. In this study, we explored the utility of 99mTc-MIBI SPECT/CT for the differentiation of these tumors based on the hypothesis that the large number of mitochondria in oncocytomas would lead to increased 99mTc-MIBI uptake.

Patients and methods: In total, 6 patients (3 with oncocytoma and 3 with RCC) were imaged with 99mTc-MIBI SPECT/CT. Relative quantification was performed by measuring tumor-to-normal renal parenchyma background ratios.

Results: All 3 oncocytomas demonstrated radiotracer uptake near or above the normal renal parenchymal uptake (range of uptake ratios, 0.85-1.78). In contrast, the 3 RCCs were profoundly photopenic relative to renal background (range of uptake ratios, 0.21-0.31).

Conclusions: 99mTc-MIBI SPECT/CT appears to be of value in scintigraphically distinguishing benign renal oncocytoma from RCC.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest and sources of funding: Supported by the Buerger Family Scholar Fund and a grant from the National Kidney Foundation of Maryland.

Figures

FIGURE 1
FIGURE 1
Line-block diagram of the imaging protocol used to obtain the planar, SPECT, and SPECT/CT images.
FIGURE 2
FIGURE 2
A, One-minute postinjection posterior dynamic planar image of patient 1 demonstrating a subtle photopenic defect in the cortex of the upper pole of the right kidney at the site of the patient’s known oncocytoma (arrowhead). The patient was status post-left nephrectomy, hence the lack of visualization of the left kidney. B, Thirty-minute postinjection posterior dynamic planar image of the same patient. There has been fill-in of the large right upper pole oncocytoma (arrowhead) with relative retention of radiotracer in the mass higher than that in the surrounding normal renal parenchyma.
FIGURE 3
FIGURE 3
Representative images of the oncocytomas included in this study. A, Axial contrast-enhanced CT, axial SPECT (B), and axial SPECT/CT fusion images of a right upper pole oncocytoma (C) with a representative histologic image (D, hematoxylin and eosin stain [HE] ×20) (patient 1, white and black arrowheads). E, Axial contrast-enhanced T1-weighted MRI, axial SPECT (F), and axial SPECT/CT fusion images of a right medial interpolar oncocytoma (G) with an accompanying histologic image (H, HE ×20) (patient 2, white and black arrowheads). I, Coronal contrast-enhanced CT, coronal SPECT (J), and coronal SPECT/CT fusion images of a right lower pole oncocytoma (K) with a corresponding histologic image (L, HE ×20) (patient 3, white and black arrowheads).
FIGURE 4
FIGURE 4
Representative images of the RCCs included in this study. A, Coronal contrast-enhanced CT, coronal SPECT (B), and coronal SPECT/CT fusion images of a left upper pole Fuhrman grade III clear cell RCC (C) with a representative histologic image (D, HE ×20) (patient 4, white and black arrowheads). E, Axial contrast-enhanced CT, axial SPECT (F), and axial SPECT/CT fusion images of a medial left lower pole unclassified RCC (G) with a corresponding histologic image (H, HE ×20) (patient 5, white and black arrowheads). I, Axial contrast-enhanced CT, axial SPECT (J), and axial SPECT/CT fusion images of an Xp11 translocation RCC (K) with a histologic image (L, HE ×20) (patient 6, white and black arrowheads).

References

    1. Gill IS, Aron M, Gervais DA, et al. Clinical practice. Small renal mass. N Engl J Med. 2010; 362: 624– 634. - PubMed
    1. Hollingsworth JM, Miller DC, Daignault S, et al. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst. 2006; 98: 1331– 1334. - PubMed
    1. Frank I, Blue ML, Cheville JC, et al. Solid renal tumors: an analysis of pathological features related to tumor size. J Urol. 2003; 170: 2217– 2220. - PubMed
    1. Pierorazio PM, Hyams ES, Tsai S, et al. Multiphasic enhancement patterns of small renal masses (≤4 cm) on preoperative computed tomography: utility for distinguishing subtypes of renal cell carcinoma, angiomyolipoma, and oncoctyoma. Urology. 2013; 81: 1265– 1271. - PMC - PubMed
    1. Pedrosa I, Sun MR, Spencer M, et al. MR imaging of renal masses: correlation with findings at surgery and pathologic analysis. Radiographics. 2008; 28: 985– 1003. - PubMed

Publication types

Substances

Supplementary concepts